19,563 Shares in MannKind Co. (NASDAQ:MNKD) Bought by AJOVista LLC

AJOVista LLC bought a new position in MannKind Co. (NASDAQ:MNKD) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 19,563 shares of the biopharmaceutical company’s stock, valued at approximately $71,000.

A number of other institutional investors have also added to or reduced their stakes in MNKD. Teacher Retirement System of Texas lifted its position in MannKind by 4.7% during the third quarter. Teacher Retirement System of Texas now owns 75,049 shares of the biopharmaceutical company’s stock valued at $310,000 after purchasing an additional 3,402 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in MannKind by 99.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 6,892 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 3,428 shares in the last quarter. Alps Advisors Inc. increased its stake in MannKind by 2.0% in the third quarter. Alps Advisors Inc. now owns 198,090 shares of the biopharmaceutical company’s stock valued at $818,000 after acquiring an additional 3,812 shares during the last quarter. Swiss National Bank raised its position in MannKind by 1.0% during the third quarter. Swiss National Bank now owns 581,000 shares of the biopharmaceutical company’s stock valued at $2,400,000 after purchasing an additional 5,700 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its stake in MannKind by 23.9% during the fourth quarter. Victory Capital Management Inc. now owns 35,064 shares of the biopharmaceutical company’s stock worth $128,000 after purchasing an additional 6,753 shares during the last quarter. 49.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on MNKD. Wedbush reissued an “outperform” rating and set a $10.00 price objective on shares of MannKind in a report on Wednesday, February 28th. Cantor Fitzgerald reissued an “overweight” rating and set a $6.50 price target on shares of MannKind in a research note on Friday, March 15th.

MannKind Stock Performance

MNKD traded up $0.01 on Friday, hitting $4.39. 1,836,337 shares of the company were exchanged, compared to its average volume of 1,946,563. MannKind Co. has a 12 month low of $3.17 and a 12 month high of $5.75. The firm has a fifty day simple moving average of $4.42 and a two-hundred day simple moving average of $3.92. The stock has a market capitalization of $1.19 billion, a PE ratio of -87.80 and a beta of 1.34.

MannKind (NASDAQ:MNKD) last announced its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.02. The firm had revenue of $58.47 million for the quarter, compared to analysts’ expectations of $52.36 million. On average, equities analysts expect that MannKind Co. will post 0.1 earnings per share for the current year.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.